Floatz logo

Cosibelimab

Skin Cancer

Dana-Farber Cancer InstitutePhase 4 / ApprovedActive
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Skin Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Dana-Farber Cancer Institute
Phase 4BBB
Cyclophosphamide
Institute of Oncology Ljubljana
Phase 2BB
Rapamycin
Dana-Farber Cancer Institute
Phase 4BB
Nivolumab
7 Hills Pharma, LLC
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Toray Industries, Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Cosibelimab is also rated in:

skin squamous cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →